Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term treatment. Found 24 abstracts

no pagination
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20.
Hoppe RT, Advani RH, Ai WY, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J, Nccn Clinical Practice Guidelines, Rbone Pp VP, Nellos Gp VP, Nellos Gp VP. NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):1020-58.   PMCID: not NIH funded
Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU international. 2011 Sep;108(5):701-5.   PMCID: not NIH funded
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES. Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 2011 Mar;9(3):280-317.   PMCID: not NIH funded
Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao SW, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A, Nccn Clinical Practice Guidelines. Venous Thromboembolic Disease. Journal of the National Comprehensive Cancer Network. 2011 Jul;9(7):714-77.   PMCID: not NIH funded
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-Related Fatigue. Journal of the National Comprehensive Cancer Network. 2010 Aug;8(8):904-31.   PMCID: not NIH funded
Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. Journal of Urology. 2010 Jul;184(1):69-73.   PMCID: NIH funded
Kim HJ, Barsevick AM, Tulman L. Predictors of the Intensity of Symptoms in a Cluster in Patients With Breast Cancer. Journal of Nursing Scholarship. 2009 Jan;41(2):158-65.   PMCID: PMC2884278
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):667-71.
Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leukemia & lymphoma. 2004 Oct;45(10):2079-84.
Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Therapy. 2002 Oct;9(10):807-12.
Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R. Patterns of breast carcinoma treatment in older women - Patient preference and clinical and physician influences. Cancer. 2000 Aug;89(3):561-73.
Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using rtog 90-06. International Journal of Radiation Oncology Biology Physics. 1998 Jan;40(1):51-5.
Das IJ, Cheng CW, Fein DA, Fowble B. Patterns of dose variability in radiation prescription of breast cancer. Radiotherapy and Oncology. 1997 Jul;44(1):83-9.
Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia LR. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. International Journal of Radiation Oncology Biology Physics. 1997 Feb;37(3):543-50.
Teshima T, Hanks GE, Hanlon AL, Peter RS, Schultheiss TE. Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity. International Journal of Radiation Oncology Biology Physics. 1997 Aug;39(1):77-83.
Feitelson MA, Duan LX, Guo JH, Blumberg BS. X-Region Deletion Mutants Associated with Surface Antigen- Positive Hepatitis-B Virus-Infections. Gastroenterology. 1995 Jun;108(6):1810-9.
Russo J, Russo IH. Hormonally Induced-Differentiation - a Novel-Approach to Breast-Cancer Prevention. Journal of cellular biochemistry. 1995 Jan;:58-64.
Hanks GE, Hanlon A, Owen JB, Schultheiss TE. Patterns of Radiation Treatment of Elderly Patients with Prostate-Cancer. Cancer. 1994 Oct;74(7):2174-7.
Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. Psa Confirmation of Cure at 10 Years of T-1b, T-2, N-0, M(0) Prostate-Cancer Patients Treated in Rtog Protocol-7706 with External-Beam Irradiation. International Journal of Radiation Oncology Biology Physics. 1994 Sep 30;30(2):289-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term treatment

treatment cancer radiotherapy carcinoma chemotherapy prostate cancer radiation-therapy NCCN Guidelines therapy survival NCCN Clinical Practice Guidelines bone-marrow-transplantation age transplantation high-dose therapy antigen radical nephroureterectomy management stem-cell transplantation stem-cell care transitional cell carcinoma breast cancer elderly radiation endoscopic transitional-cell carcinoma kidney endoscopic variceal ligation 1st complete remission low-molecular-weight heparin randomized controlled-trial dose reverse transcription hodgkins-disease survivors wild-type p53 irradiation trans-retinoic acid Non-Hodgkin Lymphoma hcg 12-dimethylbenzanthracene human chorionic-gonadotropin biopsy risk myelodysplastic syndrome fatigue anticoagulation conservative surgery chemotherapeutic agents iii-promoters Symptom clusters bone marrow transplantation prevention tamoxifen budd-chiari-syndrome relapsed Hodgkin lymphoma phase-iii controlled-trial hydrocortisone randomized trial patterns of care placebo-controlled trial Male bcnu term follow-up cytogenetics 2007 doloff da-v5-ps1 adverse effects gene product(s) prognosis bis-chlorethyl nitrosourea Female kinase-activity validation follicular lymphoma prescription points Hodgkin disease deep venous acute myeloid breast carcinoma antisense postoperative gene acute promyelocytic leukemia leukemia Pyrazines ureter recursive partitioning analysis FATIGUE l-carnitine supplementation vena-cava filters pulmonary embolism susceptibility experience topical thromboembolism younger adults late rectal interruptions urothelial adenocarcinoma doubling time rat mammary-gland symptom management Adult DIAGNOSIS Survival Analysis patterns chronic liver-disease deep-vein lymphocyte predominance external-beam radiation Middle Aged tumorigenicity radiation therapy international normalized ratio surgery cancer-patients ADJUVANT CHEMOTHERAPY symptom assessment 80 and over Aged warfarin thrombosis carcinogenesis morbidity 2007 doloff da-v5-ps23 carmustine prognostic factors malignant melanoma complication late morbidity conserving positron-emission-tomography lymphoma distributions Bortezomib heparin quality-of-life mortality prophylaxis cell-growth study-group ghsg autologous blood conserving surgery women viral replication isocentric technique prostatic specific antigen combination chemotherapy disease patients screening
Last updated on Sunday, July 12, 2020